Safety, Tolerability and Immunogenicity of a Booster Dose of ZOSTAVAX Administered ≥10 Years After a First Dose Compared With a First Dose of ZOSTAVAX [EXTENSION OF 700006658]
Phase of Trial: Phase III
Latest Information Update: 28 Aug 2018
Price : $35 *
At a glance
- Drugs Varicella zoster virus vaccine live (Primary)
- Indications Varicella zoster virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme
- 28 Aug 2018 Results published in the Journal of Infectious Diseases.
- 24 Mar 2016 Primary end points has been modified.
- 16 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.